[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Ulster\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":199},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,90,116,143,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100548807","adiposity-and-iron-requirements-in-pregnancy-100548807",false,"NCT06425796","Adiposity and Iron Requirements in Pregnancy","Impact of Maternal Adiposity on Maternal Iron Status and Requirements: a Randomised Intervention Study","ADIPREG","Inclusion Criteria:- Pregnant women\n\n* Age ≥ 18 years\n* BMI ≥18.5 kg\u002Fm2\n* Without current pregnancy complications (for example, severe bleeding, Diabetes Mellitus, hyperemesis gravidarum, ectopic and molar pregnancies)\n* At least 12 Gestational Week\n* Singleton pregnancy confirmed with the first ultrasound scan\n* Participants who are currently taking multivitamins will be included. They will be asked to discontinue any current supplementation.\n\nExclusion Criteria:\n\n* Hb \\\u003C110 g\u002FL\n* SF \\\u003C30 μg\u002FL\n* High risk of iron overload (Hb \\>150 g\u002FL, transferrin saturation \\>45% or SF\\> 150 μg\u002FL)\n* Participants with history of haematological, renal, liver, autoimmune disorders, malabsorptive syndromes\n* Participants with history of bariatric surgery\n* Participants who take steroids or anti-inflammatory treatments or drugs that affect gut absorption (proton-pump inhibitors)\n* Planned home births\n* Participants currently involved in another research study\n* Multiple pregnancy\n* Participants who do not speak English",true,"FEMALE","18 Years",{"count":21,"type":22},312,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to explore how body fat influences the response to either 25 or 50 mg of daily iron supplements during pregnancy. We will conduct a double-blind randomized controlled intervention study involving 312 pregnant women recruited from antenatal clinics in the Northern Trust Area. Participants will be randomly assigned to receive either 25 or 50 mg of iron per day from 12 weeks of pregnancy until delivery, using the Active Iron supplement brand. Blood samples will be collected at 12, 28 and 36 weeks gestation and umbilical cord blood will be collected at delivery. Anthropometric measurements will be taken at each visit, and participants will complete questionnaires on various aspects of health and lifestyle, mental health, gastrointestinal symptoms, and compliance.",[28],"Iron Deficiency Anemia of Pregnancy",[30,31,32,33,34,35,36,37,38,39,40],"Iron status","Iron Supplements","Pregnancy","Anaemia","Maternal obesity","Maternal Overweight","Body composition","Ferritin","Inflammation","Mental Health","Neonatal anaemia","RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-01","ACTUAL",{"date":47,"type":45},"2024-05-20",{"date":49,"type":22},"2027-03-19",{"name":51,"class":52},"University of Ulster","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":19,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100641853","bloodtrackr-usability-and-concordance-study-bucs-evaluating-a-smart-home-based-blood-collection-platform-for-remote-monitoring-in-rheumatoid-arthritis-100641853","NCT07660029","BloodTrackR Usability and Concordance Study (BUCS): Evaluating a Smart Home-Based Blood Collection Platform for Remote Monitoring in Rheumatoid Arthritis","BloodTrackR Usability and Concordance Study (BUCS)","BUCS","Inclusion Criteria:\n\n* Individuals living with rheumatoid arthritis, who attend community groups or rheumatoid arthritis charity groups\n* Aged 18 years or older\n* Able to understand written and spoken English\n* Individuals who have the capacity to consent\n* Access to WiFi and a smartphone\u002Ftablet\n\nExclusion Criteria:\n\n* Participants \\\u003C18years\n* Participants taking antibiotics\u002Fantivirals\n* No access to WiFi or a smartphone\u002Ftablet","ALL",{"count":64,"type":22},20,"OBSERVATIONAL","The BloodTrackR Usability and Concordance Study (BUCS) is evaluating a novel home-based blood collection device and companion mobile application for people with rheumatoid arthritis. Participants will use the BloodTrackR device to collect a finger-prick blood sample at home and complete symptom assessments through the app.\n\nThe study will assess how easy the device and app are to use, whether participants can successfully collect high-quality blood samples outside of a healthcare setting, and how closely the results compare with standard venous blood samples collected by a phlebotomist. Findings will help determine the potential of BloodTrackR to support remote monitoring and reduce reliance on NHS phlebotomy services.",[68,69],"Rheumatoid Arthritis (RA)","Remote Patient Monitoring",[71,72,69,73,74,75,76,77,78,79,80],"Rheumatoid Arthritis","Home Blood Collection","BloodTrackR","Blood Microsampling","CRP","Usability Study","Concordance Study","Digital Health","Mobile Health","Remote Monitoring","2026-06-19",{"date":83,"type":45},"2026-06-24",{"date":85,"type":22},"2026-06",{"date":87,"type":22},"2026-12",{"name":51,"class":52},1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":62,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":115,"locationsCount":89},"100639993","effect-of-a-food-intervention-with-a-prebiotic-alone-or-combined-with-b-vitamins-on-gut-microbiota-diversity-inflammation-and-mental-health-outcomes-in-older-adults-gutfood-100639993","NCT07592975","Effect of a Food Intervention With a Prebiotic Alone or Combined With B-vitamins on Gut Microbiota Diversity, Inflammation and Mental Health Outcomes in Older Adults (GutFood)","'GutFood' - Effect of a Food Intervention With a Prebiotic Alone or Combined With B-vitamins on Gut Microbiota Diversity, Inflammation and Mental Health Outcomes in Older Adults","Inclusion Criteria:\n\n* Community-dwelling\n* Non or low consumers (≤ 4 portions\u002Fweek) of foods\u002Fbeverages fortified with B-vitamins\n* Individuals with the capacity to provide informed consent\n\nExclusion Criteria:\n\n* B12 injection users\n* Using supplements containing the nutrients of interest (B-vitamins, inulin, probiotics)\n* Taking medications that interfere with B-vitamin metabolism\n* Currently taking antibiotics\n* GI disease (Crohn's, coeliac)\n* Serious chronic disease (e.g. cancer, liver disease)","50 Years",{"count":99,"type":22},84,[25],"Ageing is associated with changes in gut microbiota composition, increased inflammation, and a greater risk of poor mental health outcomes. Nutritional inadequacies, including low dietary fibre intake and suboptimal B-vitamin status, are common in older adults and may contribute to these age-related health issues. Research suggests that increasing dietary fibre intake, particularly through prebiotics such as inulin, may help to improve gut health. In addition, B-vitamins have been linked to both gut and mental health, although their combined effects with prebiotics are not well understood.\n\nWith the assistance of a food company, the investigators have developed a functional drink enriched with chicory inulin, alone or in combination with B-vitamins. Therefore, the investigators plan to conduct a 12-week randomised, double-blind, placebo-controlled trial to test the effect of this functional drink on gut health outcomes, nutritional status, inflammation, and mental health in adults aged 50 years and older.",[103],"Biomarkers of B-vitamin Status and Gut Microbiome Composition",[105,106,107,108,109],"Functional food","Healthy ageing","B-vitamin status","Gut microbes","Inulin","2026-05-11",{"date":112,"type":45},"2026-05-18",{"date":112,"type":22},{"date":87,"type":22},{"name":51,"class":52},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":62,"minAge":19,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100567385","to-test-an-e-health-educational-intervention-patients-with-an-icd-100567385","NCT06667505","To Test an e-Health Educational Intervention Patients With an ICD","To Co-develop and Test an eHealth Intervention to Improve Knowledge, Attitude and Experience in Patients Living With an Implantable Cardioverter Defibrillator","CHOICE-ICD","Inclusion Criteria:\n\n* Patients with heart failure awaiting or with an ICD (no time restriction on implantation)\n* No cognitive impairment\n\nCaregivers:\n\n* Have contact with the patient at least 5 times per week.\n* Be physically and mentally capable of participation (self-assessment)\n\nHealthcare professionals:\n\n* Daily care of patients with heart failure and an implantable cardioverter defibrillator\n* Involved in the care of a patient using the Choice-ICD intervention\n\nExclusion Criteria:\n\n* Patients, judged by their Cardiologist as physically or mentally unsuitable to complete the study.\n* Patients or caregivers lacking capacity to give consent.\n* Patients who have known pregnancy\n* Caregivers who's patient is unwilling to take participate",{"count":125,"type":22},256,[25],"Role of the implantable cardioverter defibrillator (ICD) is to monitor heart rate and discharge a small electrical discharge or shock if the heart rate becomes life threatening. Patients and family members have requested more information about their ICD, how it works and how to live well with the device. This study will build on previous research by designing, in collaboration with patients, family members and professionals, an online resource to provide important information that can lower anxiety and concerns, and improve quality of life. The CHOICE-ICD resource will be easy to use, incorporating games and quizzes to encourage engagement, up to date information appropriate to each patient's needs, as well as animation clips, virtual reality, and short patient videos. CHOICE-ICD will be made available to 64 patients, in addition to normal care, awaiting or with a recently implanted ICD in Belfast and Glasgow. Patients will use the resource for 3 months. Patients and family members will then be asked to complete questionnaires and participate in semi-structured interviews. This study will develop 1st UK online resource providing information to enable patients to have greater choice and control in their care.",[129],"Implantable Cardioverter Defibrillator (ICD)",[131,132,133],"Implantable cardioverter defibrillatior","e-Health intervention","patient education","2026-04-28",{"date":136,"type":45},"2026-05-05",{"date":138,"type":45},"2025-08-11",{"date":140,"type":22},"2026-12-01",{"name":51,"class":52},2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":17,"sex":62,"minAge":97,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":89},"100610368","microbiota-mediated-flavonoid-metabolites-for-cognitive-health-100610368","NCT07226674","Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE","Inclusion Criteria:\n\n* 50+ years\n* BMI ≥ 25 kg\u002Fm2\n* Enhanced risk of AD - defined as family history of AD, 1st degree family member\n* Habitually consume suboptimal diets such as typical Western diet (i.e., high in animal products, refined carbohydrates and processed food).\n* Subjects capable of and willing to comply with the protocol and to give their written informed consent.\n\nExclusion Criteria:\n\n* Cognitive impairment at time of recruitment into the study, as measured by the Mini Mental Status Exam (MMSE, score 25-30), and Clinical Dementia Rating (CDR, score=0) or Everyday Cognition Scale-12 (ECog-12, score\\\u003C1.36 included).\n* Pre-existing psychosis or psychiatric conditions.\n* Currently receiving treatment for dementia.\n* History of substance abuse or cerebrovascular events.\n* Heavy use of tobacco (\\>1\u002F2 pack per day)\n* Any intolerance or allergy documented or suspected to one of the components of the study products.\n* Have taken probiotics or antibiotic therapy within the last 1 month\n* Change in medication use in the last 3 months.\n* Frailty, malnutrition, or food allergy\u002Fintolerance requiring special diets will also be excluded.\n* Following any specific diet (vegetarian, vegan, etc.)\n* Body weight at enrolment greater than 400lbs due to weight restrictions on the MRI table.\n* Pregnant, breastfeeding, postpartum for less than 6 months, or unwilling to practice birth control during participation in the study.\n* Unable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, or metallic foreign body, etc.)\n* Chronic pain.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Having a psychological or linguistic inability to sign the informed consent;\n* Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;\n* Subject participating in another biomedical study or participation in another study within the 3 months before entry into this study.",{"count":152,"type":22},100,[25],"Globally, populations are ageing increasing the prevalence of Alzheimer's disease (AD), due to lack of effective treatments. The traditional Mediterranean diet, rich in fibre and polyphenols (PPs) can help prevent or delay cognitive dysfunction and preserve healthy brain structure and function. Cognitive decline is inversely associated with higher PP intakes (\\>421mg\u002Fday) i.e., total flavonoids, flavan-3-ols and flavonoid oligomers. The positive brain effects of flavonoid intake are likely mediated in part by gut microbial PP metabolites, consistent with the emerging role of the brain-gut microbiome (BGM) system in neurodegeneration. Our preliminary data indicate that circulating phenyl-γ-valerolactones (PVL), neuroprotective compounds exclusively produced by gut microbiota from flavan-3-ol rich foods18 are associated with delaying cognitive dysfunction. Intake of PPs change gut microbial composition and function, altering the physiology of the host's secondary bile acid (BA) pool through modulation of bacterial 7α-dehydroxylation of de-conjugated primary BAs into secondary BAs. This is noteworthy as 7α-dehydroxylation of BAs does not happen in the brain and because gut microbial BA metabolites have regulatory and signalling functions in the brain. The ratio between certain primary and secondary BAs is also dysregulated in AD with significantly lower serum concentrations of cholic acid (a primary BA) and increased levels of deoxycholic acid (a bacterially produced secondary BA). The increased ratio of cholic acid to deoxycholic acid is correlated with cognitive decline. Increased levels of tyrosine, tryptophan, purine, and tocopherol have also been identified in postmortem AD brains. However, specific pathways and mechanisms underlying these associations are unclear. In this multi-PI application by leaders in the field of BGM interactions, we leverage the collectively (NIH, HSC, SFI) funded Tripartite US-Ireland R\\&D Partnership Program to determine the mechanisms involved in PP intake on maintaining healthier cognitive and brain function, as mediated by gut microbiota metabolites of PP and BAs in 50+ year old elderly with enhanced AD risk.",[156,157],"Cognitive Decline","Cognitive Dysfunction",[159,160,161,162],"Polyphenols","Mediterranean Diet","Gut Microbiome","Alzheimer Disease","2025-11-21",{"date":165,"type":45},"2025-11-24",{"date":167,"type":22},"2025-11-25",{"date":169,"type":22},"2028-01",{"name":51,"class":52},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":62,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100349236","awareness-detection-and-communication-in-disorders-of-consciousness-100349236","NCT03827187","Awareness Detection and Communication in Disorders of Consciousness","EEG Based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability","Study 1 - Initial assessment\u002Fscreening\n\nInclusion Criteria:\n\n* Disorder of consciousness or low awareness state diagnosis ranging from unclear diagnosis in low awareness states, vegetative state and minimally conscious diagnosis. Those with locked in syndrome \u002F completed locked in syndrome resulting from injury or disease e.g., motor neuron disease who do not have health problems that would preclude them from participating may be assessed but considered as a separate cohort to those with low awareness states.\n* acute, post-acute patients where appropriate\n\nExclusion Criteria:\n\n* Participants with brain related diseases or illnesses (e.g., progressive neurological condition or uncontrolled epilepsy) or suffer from pain (these may adversely affect the brain data produced) and are deemed to be unsuitable for the trials by clinical teams.\n* Current consumption of medications that cause excessive fatigue or adversely affect cognitive functioning\n* Where English is not the individual's first language\n* Participant with excessive uncontrollable arm or head movement or teeth grinding as EEG signal quality will be degraded significantly.\n\nStudy 2 - BCI training\n\nInclusion Criteria:\n\n\\- Those identified in study 1 to have a level of awareness based on observed appropriate brain activations and\u002For those who have known awareness but are target groups for movement independent assistive devices and technologies controlled using a brain-computer interface.\n\nExclusion Criteria:\n\n\\- Participants who have shown no active brain responses in study 1 where the difference between baseline","10 Years","80 Years",{"count":181,"type":22},30,[25],"STUDY OVERVIEW Brain injury can result in a loss of consciousness or awareness, to varying degrees. Some injuries are mild and cause relatively minor changes in consciousness. However, in severe cases a person can be left in a state where they are \"awake\" but unaware, which is called unresponsive wakefulness syndrome (UWS, previously known as a vegetative state). Up to 43% of patients with a UWS diagnosis, regain some conscious awareness, and are then reclassified as minimally conscious after further assessment by clinical experts. Many of those in the minimally conscious state (MCS) and all with unresponsive wakefulness syndrome (UWS) are incapable of providing any, or consistent, overt motor responses and therefore, in some cases, existing measures of consciousness are not able to provide an accurate assessment. Furthermore, patients with locked-in syndrome (LIS), which is not a disorder of consciousness as patients are wholly aware, also, struggle to produce overt motor responses due to paralysis and anarthria, leading to long delays in accurate diagnoses using current measures to determine levels of consciousness and awareness. There is evidence that LIS patients, and a subset of patients with prolonged disorders of consciousness (DoC), can imagine movement (such as imagining lifting a heavy weight with their right arm) when given instructions presented either auditorily or visually - and the pattern of brain activity that they produce when imagining these movements, can be recorded using a method known as electroencephalography (or EEG). With these findings, the investigators have gathered evidence that EEG-based bedside detection of conscious awareness is possible using Brain- Computer Interface (BCI) technology - whereby a computer programme translates information from the users EEG-recorded patterns of activity, to computer commands that allow the user to interact via a user interface. The BCI system for the current study employs three possible imagined movement combinations for a two-class movement classification; left- vs right-arm, right-arm vs feet, and left-arm vs feet. Participants are trained, using real-time feedback on their performance, to use one of these combinations of imagined movement to respond to 'yes' or 'no' answer questions in the Q\\&A sessions, by imagining one movement for 'yes' and the other for 'no'. A single combination of movements is chosen for each participant at the outset, and this participant-specific combination is used throughout their sessions. The study comprises three phases. The assessment Phase I (sessions 1-2) is to determine if the patient can imagine movements and produce detectable modulation in sensorimotor rhythms and thus is responding to instructions. Phase II (sessions 3-6) involves motor-imagery (MI) -BCI training with neurofeedback to facilitate learning of brain activity modulation; Phase III (sessions 7-10) assesses patients' MI-BCI response to closed questions, categorized to assess biographical, numerical, logical, and situational awareness. The present study augments the evidence of the efficacy for EEG-based BCI technology as an objective movement-independent diagnostic tool for the assessment of, and distinction between, PDoC and LIS patients.",[185,186,187,188,189],"Disorder of Consciousness","Paralysis","Motor Neuron Disease","Stroke","Physical Disability","2024-12-09",{"date":192,"type":45},"2024-12-13",{"date":194,"type":45},"2022-02-08",{"date":196,"type":22},"2026-08",{"name":51,"class":52},18,""]